Core Insights - Liminatus Pharma, Inc. has initiated a strategic internal review to explore the potential formation of a dedicated digital asset investment vehicle [1][2] - The prospective subsidiary aims to diversify the company's long-term treasury strategy and will operate independently from its core clinical pipeline [2] - If approved, the company anticipates targeting up to $500 million in potential capital formation through various financing tools [3] Company Overview - Liminatus Pharma is a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies [6] - The company is advancing a pipeline of novel therapies that target cancer antigens and tumor-specific immune responses [6] - Liminatus is committed to responsible innovation in capital strategy to support its long-term scientific and operational objectives [6] Current Status - No capital has been raised or committed, and no agreements or partnerships have been established at this stage [4] - The internal review is subject to final Board approval, regulatory compliance, and prevailing market conditions [4][5] - The company is working with legal, financial, and regulatory advisors to determine the optimal structure and compliance framework for the proposed initiative [5]

Core Viewpoint - Liminatus Pharma, Inc. has engaged Digital Offering LLC as its exclusive placement agent to explore innovative treasury-backed financing options to strengthen its capital structure [1][2][4] Group 1: Engagement and Strategy - The engagement with Digital Offering supports Liminatus's review of a digital asset treasury strategy, evaluating modern financial tools for capital structure enhancement [2][4] - The potential funding initiative may involve various exempt financing structures, including convertible debentures and equity-linked securities, compliant with U.S. securities laws [2][4] Group 2: Role of Digital Offering - Digital Offering is tasked with sourcing institutional and digital asset-focused investors and structuring a compliant financing solution for Liminatus [3][4] - The partnership aims to explore strategic funding opportunities in both traditional markets and the evolving digital asset landscape [4] Group 3: Company Overview - Liminatus is a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies, advancing a pipeline of novel therapies [6] - The company is committed to responsible innovation in its capital strategy to support long-term scientific and operational objectives [6]